Haw Par Corporation Limited (HAWPY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Haw Par Corporation Limited (HAWPY) with AI Score 50/100 (Hold). Haw Par Corporation Limited is a Singapore-based company focused on healthcare products, primarily manufacturing and distributing topical analgesics under the Tiger Balm and Kwan Loong brands. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Haw Par Corporation Limited (HAWPY) Healthcare & Pipeline Overview
Haw Par Corporation Limited, based in Singapore, manufactures and distributes healthcare products, notably Tiger Balm, across Asia and internationally. The company diversifies its revenue streams through investments in securities, property ownership, and leisure alternatives like oceanariums, positioning it uniquely within the drug manufacturing sector with a blend of healthcare and investment activities.
Investment Thesis
Haw Par Corporation presents a compelling investment case due to its established brand recognition with Tiger Balm and Kwan Loong, generating consistent revenue in the healthcare sector. The company's diversified business model, including investments and property holdings, provides stability and additional income streams. With a P/E ratio of 12.38 and a high dividend yield of 9.43%, the company offers potential value and income for investors. However, potential risks include fluctuations in investment income and economic conditions affecting property values. The company's beta of 0.21 indicates low volatility compared to the market. Key catalysts include expanding the reach of its healthcare products into new markets and optimizing its investment portfolio.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.96 billion, reflecting its significant presence in the healthcare sector.
- P/E ratio of 12.38, suggesting a potentially undervalued stock compared to its earnings.
- High profit margin of 115.4%, indicating efficient operations and strong pricing power.
- Gross margin of 56.0%, demonstrating effective cost management in its manufacturing and distribution processes.
- Dividend yield of 9.43%, offering a substantial income stream for investors.
Competitors & Peers
Strengths
- Strong brand recognition with Tiger Balm.
- Diversified business model.
- High profit margin.
- Established distribution network.
Weaknesses
- Dependence on a limited number of key products.
- Exposure to fluctuations in investment income.
- Geographic concentration in Asia.
- Limited presence in developed markets outside Asia.
Catalysts
- Ongoing: Expansion of Tiger Balm product line into new international markets, particularly in emerging economies.
- Ongoing: Strategic investments in quoted securities to generate additional income.
- Upcoming: Potential acquisitions of complementary businesses in the healthcare or leisure sectors.
- Upcoming: Development and launch of new healthcare products targeting specific consumer needs.
- Ongoing: Optimization of the property portfolio to maximize rental income and occupancy rates.
Risks
- Potential: Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the U.S. Dollar, affecting ADR returns.
- Ongoing: Intense competition in the healthcare industry from established and emerging players.
- Potential: Economic downturns affecting investment income and property values.
- Ongoing: Regulatory changes in the healthcare sector impacting product approvals and marketing practices.
- Potential: Product liability claims or recalls affecting the reputation and sales of Tiger Balm.
Growth Opportunities
- Expanding Tiger Balm's market reach into new geographic regions, particularly in emerging markets with growing middle classes and increasing healthcare spending. This expansion could involve strategic partnerships, targeted marketing campaigns, and adapting product formulations to local preferences. The global market for topical pain relief is projected to reach billions of dollars, offering substantial growth potential for Haw Par.
- Developing new product lines and formulations within the healthcare segment to cater to evolving consumer needs and preferences. This could include innovative delivery methods, natural ingredients, and products targeting specific pain conditions. Investing in research and development to create differentiated products can enhance Haw Par's competitive advantage and drive revenue growth.
- Optimizing the investment portfolio to maximize returns and generate consistent income. This involves actively managing the allocation of assets, identifying undervalued securities, and diversifying investments across different sectors and geographies. Effective investment management can contribute significantly to Haw Par's overall profitability and financial stability.
- Enhancing the value of the property portfolio through strategic acquisitions, renovations, and tenant management. This could involve acquiring properties in prime locations, upgrading existing facilities, and attracting high-quality tenants. Maximizing occupancy rates and rental income can generate a stable and recurring revenue stream for Haw Par.
- Leveraging digital channels and e-commerce platforms to expand the distribution and marketing of Tiger Balm and other healthcare products. This includes developing a strong online presence, engaging with consumers through social media, and offering convenient online purchasing options. E-commerce can provide access to a wider customer base and enhance brand awareness.
Opportunities
- Expanding into new geographic markets.
- Developing new product lines.
- Optimizing the investment portfolio.
- Enhancing the value of the property portfolio.
Threats
- Intense competition in the healthcare industry.
- Stringent regulatory requirements.
- Economic downturns affecting investment income and property values.
- Currency fluctuations.
Competitive Advantages
- Strong brand recognition and reputation for Tiger Balm and Kwan Loong.
- Diversified business model with multiple revenue streams.
- Established distribution network in Asia and internationally.
- Experienced management team with a proven track record.
About HAWPY
Haw Par Corporation Limited was incorporated in 1969 and is headquartered in Singapore. The company's core business revolves around the manufacturing, marketing, and trading of healthcare products, with a primary focus on topical analgesics. Its flagship products, Tiger Balm and Kwan Loong, are widely recognized brands in Asia and beyond. These products are manufactured and distributed through the company's Healthcare segment. Beyond healthcare, Haw Par diversifies its operations through an Investments segment, which invests in quoted securities. The company also owns and leases investment properties, comprising 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Additionally, Haw Par operates leisure businesses, including oceanariums, providing family and tourist-oriented attractions. The company also leases land, buildings, and office space and offers management support services. This diversified approach allows Haw Par to maintain a presence in multiple sectors, balancing healthcare product sales with investment income and property revenue.
What They Do
- Manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands.
- Invests in quoted securities.
- Owns and leases investment properties in Singapore and Malaysia.
- Provides family and tourist-oriented leisure alternatives, such as oceanariums.
- Leases land, buildings, and office space.
- Offers management support services.
Business Model
- Generates revenue from the sale of healthcare products, primarily Tiger Balm and Kwan Loong.
- Earns income from investments in quoted securities.
- Collects rental income from investment properties.
- Derives revenue from leisure attractions, such as oceanariums.
Industry Context
Haw Par Corporation operates within the global drug manufacturing industry, which is characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market for topical analgesics, where Tiger Balm competes, is driven by consumer demand for pain relief products. The company's investment segment is subject to market volatility and economic cycles. Its property holdings are influenced by real estate market conditions in Singapore and Malaysia. Haw Par's diversified approach allows it to navigate industry-specific challenges and capitalize on opportunities across different sectors.
Key Customers
- Consumers seeking topical pain relief products.
- Tenants leasing commercial and industrial space.
- Tourists and families visiting leisure attractions.
- Investors in quoted securities.
Financials
Chart & Info
Haw Par Corporation Limited (HAWPY) stock price: Price data unavailable
Latest News
-
Is Haw Par Corporation Limited's (SGX:H02) Recent Stock Performance Influenced By Its Financials In Any Way?
Yahoo! Finance: HAWPY News · Jan 12, 2026
-
Those who invested in Haw Par (SGX:H02) three years ago are up 98%
Yahoo! Finance: HAWPY News · Dec 22, 2025
-
Haw Par (SGX:H02) Ticks All The Boxes When It Comes To Earnings Growth
Yahoo! Finance: HAWPY News · Nov 24, 2025
-
Haw Par Corporation Limited's (SGX:H02) top owners are private companies with 36% stake, while 35% is held by individual investors
Yahoo! Finance: HAWPY News · Oct 28, 2025
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HAWPY.
Price Targets
Wall Street price target analysis for HAWPY.
MoonshotScore
What does this score mean?
The MoonshotScore rates HAWPY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Is Haw Par Corporation Limited's (SGX:H02) Recent Stock Performance Influenced By Its Financials In Any Way?
Those who invested in Haw Par (SGX:H02) three years ago are up 98%
Haw Par (SGX:H02) Ticks All The Boxes When It Comes To Earnings Growth
Haw Par Corporation Limited's (SGX:H02) top owners are private companies with 36% stake, while 35% is held by individual investors
Leadership: Ee Lim Wee
CEO
Ee Lim Wee serves as the Chief Executive Officer of Haw Par Corporation Limited. Information regarding Mr. Wee's detailed career history, education, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive background.
Track Record: Due to limited information available in the provided data, a detailed track record of Mr. Wee's key achievements, strategic decisions, and company milestones under their leadership cannot be accurately assessed. Further research is necessary to evaluate their performance and contributions to Haw Par Corporation Limited.
Haw Par Corporation Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. HAWPY is traded as a Level 1 ADR, meaning it trades over-the-counter (OTC) without as stringent SEC requirements as listed stocks. This allows U.S. investors to invest in Haw Par Corporation Limited without directly dealing with foreign exchanges.
- Home Market Ticker: Singapore Exchange (SGX), Singapore
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HAWP
HAWPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HAWPY.
- Low liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- Price volatility can be higher due to limited trading activity.
- Information asymmetry can disadvantage investors.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Established brand recognition with Tiger Balm.
- Long operating history since 1969.
- Diversified business model with multiple revenue streams.
- Presence in multiple geographic markets.
Haw Par Corporation Limited Stock: Key Questions Answered
What does Haw Par Corporation Limited do?
Haw Par Corporation Limited is a diversified company primarily engaged in the healthcare sector, manufacturing and distributing topical analgesics under the well-known Tiger Balm and Kwan Loong brands. Additionally, the company has significant investments in quoted securities and owns/leases investment properties in Singapore and Malaysia. Haw Par also operates leisure businesses, including oceanariums, providing a mix of healthcare, investment, and leisure services.
What do analysts say about HAWPY stock?
Due to the limited availability of analyst coverage for HAWPY, particularly as it trades as an OTC ADR, a consensus view is not readily available. Investors should focus on the company's fundamentals, including its P/E ratio, profit margin, and dividend yield, alongside its strategic initiatives and risk factors. Monitor company announcements and financial reports for insights into its performance and future prospects.
What are the main risks for HAWPY?
HAWPY faces several risks, including currency fluctuations impacting ADR returns, intense competition in the healthcare industry, and potential economic downturns affecting investment income and property values. Regulatory changes in the healthcare sector and potential product liability claims also pose risks. As an OTC-traded ADR, HAWPY carries additional risks related to limited liquidity and disclosure requirements.
What are the key factors to evaluate for HAWPY?
Haw Par Corporation Limited (HAWPY) currently holds an AI score of 50/100, indicating moderate score. Key strength: Strong brand recognition with Tiger Balm.. Primary risk to monitor: Potential: Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the U.S. Dollar, affecting ADR returns.. This is not financial advice.
How frequently does HAWPY data refresh on this page?
HAWPY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HAWPY's recent stock price performance?
Recent price movement in Haw Par Corporation Limited (HAWPY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition with Tiger Balm.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HAWPY overvalued or undervalued right now?
Determining whether Haw Par Corporation Limited (HAWPY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HAWPY?
Before investing in Haw Par Corporation Limited (HAWPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for CEO background and track record.
- Disclosure status on OTC markets is unknown.